Marcelo Garrido

2 ta ish

1. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

   Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais +97

   MaqolaOAOchiq kirish20192 iqtibos

   ABIABI:AkademIndex/2026.other.057761

2. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial

   Yelena Y. Janjigian, Kohei Shitara, Markus Moehler +26

   Maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.596966